New drugs to treat multidrug-resistant tuberculosis: The case for bedaquiline

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 597-602

  Leibert, Eric ^a   Danckers, Mauricio ^a   Rom, William N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bedaquiline; Multidrug resistant tuberculosis; Sirturo

Indexed keywords

AMINOTRANSFERASE; BEDAQUILINE; CYCLOSERINE; CYTOCHROME P450 3A; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PLACEBO; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; TERIZIDONE;

ABNORMAL LABORATORY RESULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CLINICAL TRIAL (TOPIC); DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRON TRANSPORT; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERURICEMIA; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; TOXIC HEPATITIS; TREATMENT DURATION; VOMITING;

EID: 84905225792     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S37743     Document Type: Review

References (47)

1. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med. 2005;171(7):699-706.
2. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA. 1995;273(3):220-226.
3. Dye C. Global epidemiology of tuberculosis. Lancet. 2006;367(9514): 938-940.
4. Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol. 2012;10(6):407-416.
5. Rieder HL, Arnadottir T, Trébucq A, Enarson DA. Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis. 2001;5(1):1-3.
6. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed June 13, 2014.
7. Gandhi NR, Moll A, Sturm AW, etal. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575-1580.
8. Blumberg HM, Burman WJ, Chaisson RE, etal; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-662.
9. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329(11):784-791.
10. Law KF, Jagirdar J, Weiden MD, Bodkin M, Rom WN. Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med. 1996;153(4 Pt 1):1377-1384.
11. Nakata K, Rom WN, Honda Y, etal. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med. 1997;155(3):996-1003.
12. Abdool Karim SS, Naidoo K, Grobler A, etal. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16): 1492-1501.
13. Blanc FX, Sok T, Laureillard D, etal; CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16): 1471-1481.
14. Havlir DV, Kendall MA, Ive P, etal; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491.
15. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clinical Pharmacokinetics. 2001;40(5):327-341.
16. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [webpage on the Internet]. Atlanta: Centers for Disease Control and Prevention; 2013. Available from: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm. Accessed June 13, 2014.
17. Nachega JB, Rosenkranz B, Simon G, Chaisson RE, Diacon A, Taljaard J. Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives. Infect Disord Drug Targets. 2011;11(2):134-143.
18. Leistikow RL, Morton RA, Bartek IL, Frimpong I, Wagner K, Voskuil MI. The Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy. J Bacteriol. 2010;192(6):1662-1670.
19. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980;121(6):939-949.
20. Boshoff HI, Barry CE 3rd. Tuberculosis-metabolism and respiration in the absence of growth. Nat Rev Microbiol. 2005;3(1):70-80.
21. Bennett DE, Courval JM, Onorato I, etal. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177(3):348-355.
22. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA. Medicine. A portfolio model of drug development for tuberculosis. Science. 2006;311(5765):1246-1247.
23. TB Alliance Interactive Portfolio [webpage on the Internet]. Global Alliance for TB Drug Development. Available from: http://www.tballiance.org/portfolio/. Accessed February 21, 2014.
24. Andries K, Verhasselt P, Guillemont J, etal. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223-227.
25. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, etal. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother. 2009;53(3):1290-1292.
26. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51(11):4202-4204.
27. Koul A, Vranckx L, Dendouga N, etal. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008;283(37):25273-25280.
28. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother. 2006;50(8):2853-2856.
29. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(1):574-576.
30. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(5):2979-2981.
31. Janssen Pharmaceutical Companies. Anti-Infective Drugs Advisory Committee Meeting Briefing Document TMC207 (bedaquiline) Treatment of Patients with MDR-TB NDA 204-384. Titusville, NJ: Janssen Pharmaceutical Companies; 2012. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm329260.pdf. Accessed February 21, 2014.
32. Nuermberger E, Mitchison DA. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med. 2009;179(1):2-3.
33. Veziris N, Ibrahim M, Lounis N, etal. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med. 2009;179(1):75-79.
34. Rustomjee R, Diacon AH, Allen J, etal. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(8): 2831-2835.
35. Diacon AH, Pym A, Grobusch M, etal. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23): 2397-2405.
36. Barry CE 3rd. Unorthodox approach to the development of a new antituberculosis therapy. N Engl J Med. 2009;360(23):2466-2467.
37. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother. 2013;57(5): 2199-2203.
38. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50(11):3543-3547.
39. Diacon AH, Donald PR, Pym A, etal. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6): 3271-3276.
40. Phase 2 open-label trial of TMC207 in an MDR-TB treatment regimen [webpage on the Internet]. Paris: International Union Against Tuberculosis and Lung Disease; 2011. Available from: http://uwclh.conference2web.com/content/1108. Accessed February 21, 2014.
41. Anti-Infective Drugs Advisory Committee Meeting [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM332961.pdf. Accessed February 21, 2014.
42. Accelerated Approval Program [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2013. Available from: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm313768.htm. Accessed February 21, 2014.
43. Sirturo™ [prescribing information]. Titusville, NJ: Janssen Pharmaceutical Companies; 2012.
44. Janssen Infectious Diseases BVBA. A study to evaluate the efficacy and safety of TMC207 in patients with pulmonary infection with multi-drug resistant Mycobacterium tuberculosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01600963?term=bedaquiline&rank=7. NLM identifier: NCT01600963. Accessed February 21, 2014.
45. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013;62(RR-09):1-12.
46. Tasneen R, Li SY, Peloquin CA, etal. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011;55(12):5485-5492.
47. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA. 2013;309(13):1349-1350.